Streetbeat News

FLHLF

Filament Health Corp

Open

0.03

Mkt cap

8.3M

Volume

2.9K

High

0.03

P/E Ratio

-3.22

52-wk high

0.15

Low

0.03

Div yield

N/A

52-wk low

0.02

Filament Health (OTCQB:FLHLF) has entered into a definitive agreement with Jupiter Acquisition Corp. (NASDAQ:JAQC) for a $210M SPAC deal. The new business combination ascribes Filament $176 million in pre-money equity and will give holders of outstanding shares $0.85 per share of the new company. The deal is expected to close in Q4 2023. Filament's lead drug candidate PEX010 is currently undergoing 15 clinical trials for the potential treatment of various disorders.

Portfolio Pulse from Lara Goldstein

July 19, 2023 | 9:41 pm

Australia has become the first country to allow physicians to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression. In the US, lawmakers are seeking to advance drug policy changes as part of the National Defense Authorization Act (NDAA), including medical cannabis access for military veterans. The American Medical Association (AMA) has published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies. COMPASS Pathways secured up to $50 million in a new term loan facility with Hercules Capital. AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, July 10 at $2.03, improving from prior Monday 3’s opening at $1.89.

Portfolio Pulse from Lara Goldstein

July 11, 2023 | 3:25 pm

Filament Health (OTCQB:FLHLF) will supply psilocybin for two clinical studies funded by the Canadian Institutes of Health Research. The company will donate its pharma-grade botanical psilocybin drug candidate PEX010 for the trials. Filament has also entered into an exclusive global licensing agreement with NeoLumina Bioscience for PEX010 and its associated IP to be developed for eating disorders. Filament will receive milestone payments and future commercial royalties on a percentage of net sales.

Portfolio Pulse from Lara Goldstein

July 07, 2023 | 7:51 pm

A Phase 1 clinical trial led by UCSF assessing Filament Health Corp.'s (OTCQB:FLHLF) botanical psychedelic drug candidates has shown positive interim outcomes. The trial administered doses of naturally-sourced psilocybin and psilocin to four healthy subjects, reporting good tolerability and no serious adverse events.

Portfolio Pulse from Lara Goldstein

May 31, 2023 | 12:23 am

Terran Biosciences discovers new psilocybin compounds, MindMed's LSD study for anxiety treatment enrolls and doses 100 participants, and PharmAla receives Health Canada's approval for MDMA treatment. UK Parliament debates accelerating psychedelics research and psilocybin rescheduling.

Portfolio Pulse from Lara Goldstein

May 23, 2023 | 11:56 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.